JP2019524687A - 抗体薬物複合体およびこれを用いた治療方法 - Google Patents
抗体薬物複合体およびこれを用いた治療方法 Download PDFInfo
- Publication number
- JP2019524687A JP2019524687A JP2018568875A JP2018568875A JP2019524687A JP 2019524687 A JP2019524687 A JP 2019524687A JP 2018568875 A JP2018568875 A JP 2018568875A JP 2018568875 A JP2018568875 A JP 2018568875A JP 2019524687 A JP2019524687 A JP 2019524687A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- drug conjugate
- broadly neutralizing
- hiv
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
- A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/112—Retroviridae (F), e.g. leukemia viruses
- C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
- C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357410P | 2016-07-01 | 2016-07-01 | |
| US62/357,410 | 2016-07-01 | ||
| PCT/IB2017/053979 WO2018002902A1 (en) | 2016-07-01 | 2017-06-30 | Antibody-drug conjugates and therapeutic methods using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019524687A true JP2019524687A (ja) | 2019-09-05 |
| JP2019524687A5 JP2019524687A5 (cg-RX-API-DMAC7.html) | 2020-08-13 |
Family
ID=59399452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018568875A Withdrawn JP2019524687A (ja) | 2016-07-01 | 2017-06-30 | 抗体薬物複合体およびこれを用いた治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190328900A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3478324A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2019524687A (cg-RX-API-DMAC7.html) |
| TW (1) | TW201811376A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018002902A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025249542A1 (ja) * | 2024-05-31 | 2025-12-04 | 国立大学法人東京科学大学 | 抗hiv抗体薬物複合体 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112638426B (zh) * | 2018-09-21 | 2023-06-16 | 中国人民解放军军事科学院军事医学研究院 | 基于芳硝基的连接子、含连接子的抗体偶联药物及连接子的用途 |
| JP2022519586A (ja) * | 2019-02-04 | 2022-03-24 | ゼネティック バイオサイエンシーズ インコーポレイテッド | 糖ポリシアル酸化治療用タンパク質を使用する方法 |
| TW202104274A (zh) * | 2019-04-09 | 2021-02-01 | 法商賽諾菲公司 | 用於治療hiv感染之三特異性及/或三價結合蛋白 |
| US20240124561A1 (en) * | 2019-10-17 | 2024-04-18 | Minicircle Inc. | Nucleic acids encoding hiv neutralizing antibodies and uses thereof |
| IL293566A (en) * | 2019-12-09 | 2022-08-01 | Viiv Healthcare Co | Pharmaceutical preparations containing Cabotgravir |
| JP2024500322A (ja) * | 2020-12-07 | 2024-01-09 | ヴィーブ、ヘルスケア、カンパニー | 併用療法 |
| IL307498A (en) | 2021-04-05 | 2023-12-01 | Altheia Science S R L | Diagnosis and treatment of myeloid disorders and acute leukemia using antigens specific to new tumors |
| CN115590976B (zh) * | 2021-06-28 | 2025-06-27 | 前沿生物药业(南京)股份有限公司 | 治疗和/或预防hiv相关疾病的apc偶联物及其制法和应用 |
| CN115590965B (zh) * | 2021-06-28 | 2024-06-28 | 前沿生物药业(南京)股份有限公司 | 用于治疗和/或预防hiv相关疾病的aptc偶联物及其应用 |
| IL313306A (en) * | 2021-12-17 | 2024-08-01 | Viiv Healthcare Co | Combined treatments for HIV infections and their uses |
| WO2023194501A1 (en) | 2022-04-05 | 2023-10-12 | Altheia Science S.R.L. | Treatment of myeloid disorders and acute leukemias targeting novel tumor specific antigens |
| WO2024245401A1 (en) * | 2023-06-01 | 2024-12-05 | Taimed Biologics Inc. | Antibody-drug conjugates for treating infections of human immunodeficiency virus (hiv) |
| CN117138104A (zh) * | 2023-09-18 | 2023-12-01 | 潍坊医学院附属医院 | 一种用于烧伤创面的抗氧化蛋白肽基纳米水凝胶 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB427857A (en) | 1934-08-02 | 1935-05-01 | Newsum Sons & Company Ltd H | A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames |
| US4107288A (en) | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| CN1192688A (zh) | 1995-06-07 | 1998-09-09 | 特莱默里斯公司 | 联合疗法治疗hiv和其它病毒性感染 |
| US20070258987A1 (en) | 2000-11-28 | 2007-11-08 | Seattle Genetics, Inc. | Recombinant Anti-Cd30 Antibodies and Uses Thereof |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| WO2002074769A1 (en) | 2001-03-19 | 2002-09-26 | Ono Pharmaceutical Co., Ltd. | Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient |
| TW200539855A (en) | 2004-03-15 | 2005-12-16 | Wyeth Corp | Calicheamicin conjugates |
| NZ551180A (en) | 2004-06-01 | 2009-10-30 | Genentech Inc | Antibody drug conjugates and methods |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| US9005889B2 (en) | 2007-01-16 | 2015-04-14 | The Johns Hopkins University | Synergistic antiviral compositions comprising a viral attachment inhibitor, integration inhibitor, and proviral transcription inhibitor |
| WO2008122039A2 (en) | 2007-04-02 | 2008-10-09 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selenocysteine mediated hybrid antibody molecules |
| US7985557B2 (en) | 2007-05-23 | 2011-07-26 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
| UA108598C2 (xx) | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
| ES2560807T3 (es) | 2008-07-21 | 2016-02-22 | Polytherics Limited | Nuevos reactivos y procedimiento de conjugación de moléculas biológicas |
| DK2889624T3 (en) | 2009-08-10 | 2018-12-10 | Ucl Business Plc | Reversible covalent bonding of functional molecules |
| AU2010292172A1 (en) | 2009-09-09 | 2012-05-03 | Centrose, Llc | Extracellular targeted drug conjugates |
| US9175070B2 (en) | 2009-09-25 | 2015-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to HIV-1 and their use |
| WO2011046623A2 (en) | 2009-10-16 | 2011-04-21 | Duke University | Hiv-1 antibodies |
| EP2515914A4 (en) * | 2009-12-23 | 2013-09-11 | Scripps Research Inst | BIOCONJUGATION OF TYROSINE BY EYE REACTIONS IN AQUEOUS MEDIA |
| PT2528625E (pt) | 2010-04-15 | 2013-10-17 | Spirogen Sarl | Pirrolobenzodiazepinas e conjugados das mesmas |
| US20130244905A1 (en) | 2010-07-06 | 2013-09-19 | Ed Grabczyk | Reporter for RNA Polymerase II Termination |
| WO2012040562A2 (en) | 2010-09-24 | 2012-03-29 | International Aids Vaccine Initiative | Novel hiv-1 broadly neutralizing antibodies |
| EP2635300A4 (en) * | 2010-11-03 | 2014-04-02 | Ibc Pharmaceuticals Inc | DOCK-AND-LOCK (DNL) CONSTRUCTS FOR THERAPY AGAINST HUMAN IMMUNE WEAKAGE VIRUS (HIV) |
| CN103282385A (zh) | 2010-11-12 | 2013-09-04 | 美国洛克菲勒大学 | 用于hiv治疗的融合蛋白 |
| WO2012106578A1 (en) | 2011-02-04 | 2012-08-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HIV NEUTRALIZING ANTIBODIES HAVING MUTATIONS IN CONSTANT DOMAIN (Fc) |
| DK2714685T3 (en) | 2011-05-27 | 2017-01-09 | Ambrx Inc | FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin |
| US8815226B2 (en) | 2011-06-10 | 2014-08-26 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates |
| EP2753644A1 (en) | 2011-09-09 | 2014-07-16 | Universiteit Utrecht Holding B.V. | Broadly neutralizing vhh against hiv-1 |
| AU2012322934B2 (en) | 2011-10-14 | 2016-09-08 | Medimmune Limited | Pyrrolobenzodiazepines |
| CA2850375C (en) | 2011-10-14 | 2019-07-02 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| JP6166728B2 (ja) | 2011-10-14 | 2017-07-19 | メドイミューン・リミテッドMedImmune Limited | ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体 |
| CA2850373C (en) | 2011-10-14 | 2019-07-16 | Seattle Genetics, Inc. | Pyrrolobenzodiazepines and targeted conjugates |
| CN104080805B (zh) | 2011-11-07 | 2017-02-22 | 美国政府健康及人类服务部 | gp41中和性抗体及其用途 |
| WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
| BR112014013526A8 (pt) | 2011-12-05 | 2017-06-13 | Igenica Biotherapeutics Inc | conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados |
| CN104271597B (zh) | 2011-12-08 | 2018-05-25 | 美国政府(由卫生和人类服务部的部长所代表) | Hiv-1的中和抗体及其用途 |
| PT2908912T (pt) | 2012-10-18 | 2020-09-04 | Univ Rockefeller | Anticorpos anti-hiv amplamente neutralizantes |
| HRP20180268T4 (hr) | 2012-10-23 | 2026-03-27 | Synaffix B.V. | Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu |
| EP2765138B1 (en) | 2012-11-05 | 2018-01-10 | International Aids Vaccine Initiative | HIV-1 envelope glycoprotein |
| US10058603B2 (en) | 2013-03-15 | 2018-08-28 | Glaxosmithkline Biologicals S.A. | Vaccine |
| TWI641620B (zh) | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗-prlr抗體及其用途 |
| EP3077051B1 (en) | 2013-12-02 | 2023-04-12 | The Trustees of Columbia University in the City of New York | Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture |
| US10093720B2 (en) | 2014-06-11 | 2018-10-09 | International Aids Vaccine Initiative | Broadly neutralizing antibody and uses thereof |
| WO2016196975A1 (en) | 2015-06-03 | 2016-12-08 | The United States Of America, As Represented By The Secretary Department Of Health & Human Services | Neutralizing antibodies to hiv-1 env and their use |
| EP4011911A1 (en) | 2015-11-03 | 2022-06-15 | The United States of America as represented by The Secretary Department of Health and Human Services | Neutralizing antibodies to hiv-1 gp41 and their use |
-
2017
- 2017-06-30 WO PCT/IB2017/053979 patent/WO2018002902A1/en not_active Ceased
- 2017-06-30 TW TW106122147A patent/TW201811376A/zh unknown
- 2017-06-30 US US16/308,862 patent/US20190328900A1/en not_active Abandoned
- 2017-06-30 EP EP17743394.3A patent/EP3478324A1/en not_active Withdrawn
- 2017-06-30 JP JP2018568875A patent/JP2019524687A/ja not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025249542A1 (ja) * | 2024-05-31 | 2025-12-04 | 国立大学法人東京科学大学 | 抗hiv抗体薬物複合体 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3478324A1 (en) | 2019-05-08 |
| TW201811376A (zh) | 2018-04-01 |
| WO2018002902A1 (en) | 2018-01-04 |
| US20190328900A1 (en) | 2019-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190328900A1 (en) | Antibody-drug conjugates and therapeutic methods using the same | |
| US11655285B2 (en) | Human immunodeficiency virus neutralizing antibodies | |
| EP2571898B1 (en) | High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins | |
| US10196438B2 (en) | Human antibodies binding to RSV G protein | |
| CA2908921C (en) | Human antibodies binding to rsv g protein | |
| US20250250328A1 (en) | Antigen Binding Proteins | |
| HK40072519A (en) | Human immunodeficiency virus neutralizing antibodies | |
| WO2025229019A1 (en) | Neutralizing antibody constructs against hiv | |
| HK40079368B (en) | Human immunodeficiency virus neutralizing antibodies | |
| HK40079368A (en) | Human immunodeficiency virus neutralizing antibodies | |
| WO2025229018A1 (en) | Neutralizing antibody constructs against hiv | |
| KR20250043336A (ko) | 클라우딘 18.2 항체, 이의 제조 방법 및 이의 용도(claudin 18.2 antibodies, methods of making the same, and uses thereof) | |
| HK1261190A1 (en) | Human immunodeficiency virus neutralizing antibodies | |
| HK40002876A (en) | Human immunodeficiency virus neutralizing antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200630 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200630 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20201111 |